Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates
US11596669B2 · kind B2 · utility
3Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2022 |
| Grant date | Mar 7, 2023 |
| Priority date | — |
| Expiry date | Mar 10, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.